Literature DB >> 2974846

Atrial natriuretic factor attenuates the pulmonary pressor response to hypoxia.

S Adnot1, P E Chabrier, C Brun-Buisson, I Viossat, P Braquet.   

Abstract

The influence of endogenous and exogenous atrial natriuretic factor (ANF) on pulmonary hemodynamics was investigated in anesthetized pigs during both normoxia and hypoxia. Continuous hypoxic ventilation with 11% O2 was associated with a uniform but transient increase of plasma immunoreactive (ir) ANF that peaked at 15 min. Plasma irANF was inversely related to pulmonary arterial pressure (Ppa; r = -0.66, P less than 0.01) and pulmonary vascular resistance (PVR; r = -0.56, P less than 0.05) at 30 min of hypoxia in 14 animals; no such relationship was found during normoxia. ANF infusion after 60 min of hypoxia in seven pigs reduced the 156 +/- 20% increase in PVR to 124 +/- 18% (P less than 0.01) at 0.01 microgram.kg-1.min-1 and to 101 +/- 15% (P less than 0.001) at 0.05 microgram.kg-1.min-1. Cardiac output (CO) and systemic arterial pressure (Psa) remained unchanged, whereas mean Ppa decreased from 25.5 +/- 1.5 to 20.5 +/- 15 mmHg (P less than 0.001) and plasma irANF increased two- to nine-fold. ANF infused at 0.1 microgram.kg-1.min-1 (resulting in a 50-fold plasma irANF increase) decreased Psa (-14%) and reduced CO (-10%); systemic vascular resistance (SVR) was not changed, nor was a further decrease in PVR induced. No change in PVR or SVR occurred in normoxic animals at any ANF infusion rate. These results suggest that ANF may act as an endogenous pulmonary vasodilator that could modulate the pulmonary pressor response to hypoxia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974846     DOI: 10.1152/jappl.1988.65.5.1975

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  14 in total

1.  Atrial natriuretic peptide.

Authors:  N Modi; J P Midgley
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Atrial natriuretic factor and postnatal diuresis in respiratory distress syndrome.

Authors:  H J Rozycki; S Baumgart
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

Review 3.  Atrial natriuretic factor: the heart as an endocrine organ.

Authors:  T J Stephenson; F Broughton Pipkin
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

4.  Effect of cyclic guanosine monophosphate on hypoxic and angiotensin-II-induced pulmonary vasoconstriction.

Authors:  K Fujimoto; A Sakai; S Yoshikawa; S Shinozaki; Y Matsuzawa; K Kubo; T Kobayashi; G Ueda; M Sekiguchi; N F Voelkel
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Atrial natriuretic peptide during and after maximal and submaximal exercise under normoxic and hypoxic conditions.

Authors:  W Schmidt; G Brabant; C Kröger; S Strauch; A Hilgendorf
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1990

6.  Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia.

Authors:  H Jin; R H Yang; Y F Chen; R M Jackson; S Oparil
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

8.  Hemodynamic and humoral effects of atrial natriuretic peptide on pulmonary circulation after cardiac surgery.

Authors:  Keisuke Morimoto; Iwao Taniguchi; Shigeto Miyasaka; Shingo Ishiguro; Shigetsugu Ohgi
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

9.  Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.

Authors:  T K Rogers; W Sheedy; J Waterhouse; P Howard; A H Morice
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

Review 10.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.